Special Issue "Peptide Vaccine"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 March 2014)
Prof. Dr. Istvan Toth
School of Chemistry and Molecular Bioscience, The University of Queensland, Brisbane QLD 4072, Australia
Interests: medicinal chemistry; drug delivery with particular interest in peptide; gene and vaccine delivery; vaccine adjuvants
Infectious diseases cause 15–17 million deaths worldwide per year, contribute to one third of premature death, and are responsible for almost 40% of human disability. Vaccination is a successful and cost effective intervention, which led to the eradication of smallpox in 1979 (confirmed by the World Health Organization), and control of polio, diphtheria, measles, and rubella, amongst other infectious diseases. The majority of current vaccines are microbe-based, either using an attenuated whole-microbe, or part thereof. Unfortunately, this approach carries the risk of stimulating an autoimmune response, the possible reversion to virulence, and is hampered by a limited shelf life. Synthetic subunit peptide antigen based vaccines offer a solution to these problems. Subunit peptide vaccines can be designed to contain the minimal microbial component necessary to stimulate an appropriate immune response. This has the advantage of removing unnecessary components, thus decreasing the risk of stimulating an autoimmune response or other adverse effects. Synthetic vaccines can also be tailored to stimulate a targeted immune response. Unfortunately, the minimal nature of synthetic peptide vaccines results in poor recognition by the immune system because they lack the ‘danger signals’ of whole microbes. Although this can be overcome by the addition of strong adjuvants (immunostimulants), alternative mechanisms must be developed to avoid this complication. This Special Issue of Vaccines contains reviews and research articles that focus on the design of peptide based vaccines.
Prof. Dr. Istvan Toth
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- peptide antigens
- subunit vaccines
- lipid based adjuvant
- polymeric adjuvants
Article: Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer’s Disease Like Tau Aggregation
Vaccines 2014, 2(3), 601-623; doi:10.3390/vaccines2030601
Received: 31 March 2014; in revised form: 11 June 2014 / Accepted: 11 June 2014 / Published: 29 July 2014| PDF Full-text (995 KB) | HTML Full-text | XML Full-text | Supplementary Files
Review: Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification
Vaccines 2014, 2(3), 549-562; doi:10.3390/vaccines2030549
Received: 25 March 2014; in revised form: 30 May 2014 / Accepted: 4 June 2014 / Published: 15 July 2014| PDF Full-text (885 KB) | HTML Full-text | XML Full-text
Vaccines 2014, 2(3), 515-536; doi:10.3390/vaccines2030515
Received: 16 April 2014; in revised form: 10 June 2014 / Accepted: 13 June 2014 / Published: 2 July 2014| PDF Full-text (692 KB) | HTML Full-text | XML Full-text
Vaccines 2014, 2(3), 537-548; doi:10.3390/vaccines2030537
Received: 9 April 2014; in revised form: 13 May 2014 / Accepted: 5 June 2014 / Published: 2 July 2014| PDF Full-text (498 KB) | HTML Full-text | XML Full-text
Vaccines 2014, 2(2), 422-462; doi:10.3390/vaccines2020422
Received: 9 April 2014; in revised form: 16 May 2014 / Accepted: 27 May 2014 / Published: 13 June 2014| PDF Full-text (911 KB) | HTML Full-text | XML Full-text
Article: Pleurocidin Peptide Enhances Grouper Anti-Vibrio harveyi Immunity Elicited by Poly(lactide-co-glycolide)-Encapsulated Recombinant Glyceraldehyde-3-phosphate Dehydrogenase
Vaccines 2014, 2(2), 380-396; doi:10.3390/vaccines2020380
Received: 31 March 2014; in revised form: 6 May 2014 / Accepted: 6 May 2014 / Published: 14 May 2014| PDF Full-text (810 KB) | HTML Full-text | XML Full-text
Last update: 29 October 2013